Silverberg Bernstein Capital Management LLC Trims Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Silverberg Bernstein Capital Management LLC lowered its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 11.3% in the 3rd quarter, HoldingsChannel reports. The firm owned 20,273 shares of the medical equipment provider’s stock after selling 2,570 shares during the quarter. Lantheus makes up about 2.0% of Silverberg Bernstein Capital Management LLC’s holdings, making the stock its 13th biggest holding. Silverberg Bernstein Capital Management LLC’s holdings in Lantheus were worth $2,225,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. UMB Bank n.a. increased its stake in shares of Lantheus by 161.4% in the 1st quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 247 shares in the last quarter. GAMMA Investing LLC increased its position in Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 208 shares during the period. Fidelis Capital Partners LLC bought a new position in Lantheus in the first quarter worth approximately $34,000. FinTrust Capital Advisors LLC lifted its holdings in Lantheus by 53.6% during the first quarter. FinTrust Capital Advisors LLC now owns 665 shares of the medical equipment provider’s stock worth $41,000 after buying an additional 232 shares during the period. Finally, Nkcfo LLC acquired a new position in Lantheus during the 2nd quarter valued at approximately $47,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Insiders Place Their Bets

In other news, CAO Andrea Sabens sold 341 shares of the business’s stock in a transaction that occurred on Monday, July 15th. The stock was sold at an average price of $123.15, for a total value of $41,994.15. Following the transaction, the chief accounting officer now owns 62,216 shares in the company, valued at $7,661,900.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Lantheus news, Director Gerard Ber sold 15,500 shares of the firm’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now directly owns 21,221 shares in the company, valued at $2,047,402.08. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CAO Andrea Sabens sold 341 shares of the firm’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $123.15, for a total transaction of $41,994.15. Following the transaction, the chief accounting officer now directly owns 62,216 shares of the company’s stock, valued at $7,661,900.40. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 40,852 shares of company stock valued at $3,922,001. Corporate insiders own 1.50% of the company’s stock.

Lantheus Stock Performance

Shares of LNTH stock traded up $1.22 during trading on Friday, reaching $107.79. 296,412 shares of the company’s stock were exchanged, compared to its average volume of 997,925. The firm’s fifty day moving average price is $103.77 and its 200-day moving average price is $87.35. The stock has a market capitalization of $7.47 billion, a PE ratio of 16.46 and a beta of 0.50. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $126.89. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). The firm had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The company’s revenue was up 22.5% compared to the same quarter last year. During the same period last year, the business earned $1.40 EPS. As a group, sell-side analysts anticipate that Lantheus Holdings, Inc. will post 5.99 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on LNTH. B. Riley boosted their target price on shares of Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. JMP Securities lowered their target price on Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a research note on Thursday, August 1st. Redburn Atlantic assumed coverage on Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price for the company. Truist Financial cut their target price on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. Finally, Leerink Partners upped their price target on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a report on Thursday, July 11th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $126.00.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.